Active ingredientFezolinetantCat. No. P-F041-001CAS 1629229-37-3Family · Pharmaceutical analytical standards
Fezolinetant
A selective NK3 receptor antagonist taken by mouth: in 2023 it was approved in the United States (May) and the European Union (December) as the first medicine of its class for menopausal hot flushes. This family brings together the active ingredient and labelled standards.
Did you know?Its target also has a genetic story: loss-of-function mutations in neurokinin B or its NK3 receptor have been found in people with idiopathic hypogonadotropic hypogonadism.
Go to the active ingredient →Active ingredientFezolinetantCat. No. P-F041-001CAS 1629229-37-3
Isotopically labelledFezolinetant-d4Cat. No. P-F041-002No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.